403
Participants
Start Date
February 19, 2015
Primary Completion Date
October 28, 2018
Study Completion Date
October 28, 2018
Dolutegravir/Abacavir/Lamivudin
Prospective, non-interventional observational study on the use of TRIUMEQ and the respective monitoring measures in the practice of HIV care in Germany. No drug will be provided. No study visits or procedures are mandated per protocol.
GSK Investigational Site, Berlin
GSK Investigational Site, Berlin
GSK Investigational Site, Berlin
GSK Investigational Site, Berlin
GSK Investigational Site, Berlin
GSK Investigational Site, Berlin
GSK Investigational Site, Berlin
GSK Investigational Site, Hamburg
GSK Investigational Site, Hamburg
GSK Investigational Site, Magdeburg
GSK Investigational Site, Düsseldorf
GSK Investigational Site, Dortmund
GSK Investigational Site, Osnabrück
GSK Investigational Site, Cologne
GSK Investigational Site, Cologne
GSK Investigational Site, Cologne
GSK Investigational Site, Aachen
GSK Investigational Site, Mainz
GSK Investigational Site, Frankfurt am Main
GSK Investigational Site, Frankfurt am Main
GSK Investigational Site, Mannheim
GSK Investigational Site, Stuttgart
GSK Investigational Site, Freiburg im Breisgau
GSK Investigational Site, Munich
GSK Investigational Site, Munich
GSK Investigational Site, Munich
GSK Investigational Site, Ulm
GSK Investigational Site, Weimar
GSK Investigational Site, Chemnitz
Lead Sponsor
Collaborators (1)
GlaxoSmithKline
INDUSTRY
ViiV Healthcare
INDUSTRY